Improving Outcomes in Schizophrenia: Advances in Treatment & Management

Supported by an educational grant from Alkermes

TITLE - Improving Outcomes in Schizophrenia: Advances in Treatment & Management

TARGET AUDIENCE - Target audiences for this program are Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Psychiatric Pharmacists, Psychiatric Nurses and Nurses

LEARNING OBJECTIVES - After completing the program, Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Psychiatric Pharmacists, Psychiatric Nurses and Nurses

  1. Discuss the neurotoxic effects of recurrent psychotic episodes on the brain to better comprehend the need for early intervention in schizophrenia
  2. Recognize available long-acting injectable (LAI) formulations of antipsychotic agents and their safety and efficacy
  3. Identify potential advantages and drawbacks of LAIs
  4. Describe factors associated with poor medication adherence in patients with schizophrenia and strategies to manage these issues to improve outcomes

Faculty Disclosures:

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/ services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by the Specialty Pharma Education Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Pharmacist continuing education credit

Specialty Pharma Education Center (SPEC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 2.0 hours (0.20CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
ACPE #0535-0000-19-022-H01-P

Knowledge Based Activity

Course release date 8/20/2019

Course expires 8/20/2022

Nursing continuing education credit

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider # 5-115. This program is approved for 2.0 hours of continuing nursing education. 

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia. 

Course release date: 8/25/2019

Course expires: 8/25/2021

Credit Information

Activity Number Credit Amount Accreditation Period
0535-0000-19-022-H01-P 0.2 CEUs August 20, 2019 - August 20, 2022
0535-0000-19-022-H01-N 2 hours of CNE August 25, 2019 - August 25, 2021